Literatur
-
1
Bousvaros A, Antonioli D A, Colletti R B. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition; Colitis Foundation of America; .
Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn’s and Colitis Foundation of America.
J Pediatr Gastroenterol Nutr.
2007;
44
653-674
-
2
Lindberg E, Lindquist B, Holmquist L, Hildebrand H.
Inflammatory bowel disease in children and adolescents in Sweden, 1984-1995.
J Pediatr Gastroenterol Nutr.
2000;
30
259-264
-
3
IBD Working Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition .
Inflammatory bowel disease in children and adolescents: recommendations for diagnosis - the Porto criteria.
J Pediatr Gastroenterol Nutr.
2005;
41
1-7
-
4
Quaglietta L, te Velde A, Staiano A, Troncone R, Hommes D W.
Functional consequences of NOD2/CARD15 mutations in Crohn disease.
J Pediatr Gastroenterol Nutr.
2007;
44
529-539
-
5
Fellermann K, Stange D E, Schaeffeler E. et al .
A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon.
Am J Hum Genet.
2006;
79
439-448
-
6
Cucchiara S, Latiano A, Palmieri O. et al .
Italian Society of Pediatric Gastroenterology and Nutrition. Polymorphisms of tumor necrosis factor-alpha but not MDR1 influence response to medical therapy in pediatric-onset inflammatory bowel disease.
J Pediatr Gastroenterol Nutr.
2007;
44
171-179
-
7
Bernstein C N, Wajda A, Blanchard J F.
The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study.
Gastroenterology.
2005;
129
827-836
-
8
Caprilli R, Gassull M A, Escher J C. et al .
European Crohn’s and Colitis Organisation. European evidence based consensus on the diagnosis and management of Crohn’s disease: special situations.
Gut.
2006;
55 Suppl 1
i36-58
-
9
Sawczenko A, Sandhu B K.
Presenting features of inflammatory bowel disease in Great Britain and Ireland.
Arch Dis Child.
2003;
88
995-1000
-
10
Walker T R, Land M L, Kartashov A. et al .
Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease.
J Pediatr Gastroenterol Nutr.
2007;
44
414-422
-
11
Canani R B, de Horatio L T, Terrin G. et al .
Combined use of noninvasive tests is useful in the initial diagnostic approach to a child with suspected inflammatory bowel disease.
J Pediatr Gastroenterol Nutr.
2006;
42
9-15
-
12
Rugtveit J, Fagerhol M K.
Age-dependent variations in fecal calprotectin concentrations in children.
J Pediatr Gastroenterol Nutr.
2002;
34
323-324
-
13
Elitsur Y, Lawrence Z, Tolaymat N.
The diagnostic accuracy of serologic markers in children with IBD: the West Virginia experience.
J Clin Gastroenterol.
2005;
39
670-673
-
14
Hyams J, Markowitz J E, Otley A. et al .
Evaluation of the pediatric Crohn disease activity index: a prospective multicenter experience.
J Ped Gastroenterol Nutr.
2005;
41
416-421
-
15
Kardorff R.
Sonographie entzündlicher Darmerkrankungen im Kindesalter. Teil 2: Akute Appendizitis und chronisch-entzündliche Darmerkrankungen.
päd praxis.
2007;
70
685-700
-
16
Hohl C, Haage P, Krombach G A. et al .
Diagnostik chronisch entzündlicher Darmerkrankungen bei Kindern und Jugendlichen: MRT mit True-FISP als neuer Goldstandard?.
Rofo (Fortschr Röntgenstr).
2005;
177
856-863
-
17
Buderus S.
Chronisch-entzündliche Darmerkrankungen: Medikamentöse Therapie im Kindes- und Jugendalter.
Monatsschr Kinderheilk.
2004;
152
133-144
-
18
Escher J C. European Collaborative Research Group on Budesonide in Paediatric IBD .
Budesonide versus prednisolone for the treatment of active Crohn’s disease in children: a randomized, double-blind, controlled, multicentre trial.
Eur J Gastroenterol Hepatol.
2004;
16
47-54
-
19
Hyams J, Crandall W, Kugathasan S. et al .
REACH Study Group. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children.
Gastroenterology.
2007;
132
863-873
-
20
Eidelwein A P, Cuffari C, Abadom V, Oliva-Hemker M.
Infliximab efficacy in pediatric ulcerative colitis.
Inflamm Bowel Dis.
2005;
11
213-218
-
21
Afzal N A, Ozzard A, Keady S, Thomson M, Murch S, Heuschkel R.
Infliximab Delays but Does Not Avoid the Need for Surgery in Treatment-Resistant Pediatric Crohn’ Disease.
Dig Dis Sci.
2007;
52
3329-3333
-
22
Durai D, Hawthorne A B.
Review article: how and when to use ciclosporin in ulcerative colitis.
Aliment Pharmacol Ther.
2005;
22
907-916
-
23
Rembacken B J, Snelling A M, Hawkey P M, Chalmers D M, Axon A T.
Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial.
Lancet.
1999;
354 (9179)
635-639
-
24
Johnson T, Macdonald S, Hill S M, Thomas A, Murphy M S.
Treatment of active Crohn’s disease in children using partial enteral nutrition with liquid formula: a randomised controlled trial.
Gut.
2006;
55
356-361
-
25
Heuschkel R B, Menache C C, Megerian J T, Baird A E.
Enteral nutrition and corticosteroids in the treatment of acute Crohn’s disease in children.
J Pediatr Gastroenterol Nutr.
2000;
31
8-15
-
26
Afzal N A, Davies S, Paintin M. et al .
Colonic Crohn’s disease in children does not respond well to treatment with enteral nutrition if the ileum is not involved.
Dig Dis Sci.
2005;
50
1471-1475
-
27
Langmead L, Rampton D S.
Review article: complementary and alternative therapies for inflammatory bowel disease.
Aliment Pharmacol Ther.
2006;
23
341-349
-
28
Maity S, Thomas A G.
Quality of life in paediatric gastrointestinal and liver disease: a systematic review.
J Pediatr Gastroenterol Nutr.
2007;
44
540-554
-
29
Mawdsley J E, Rampton D S.
Psychological stress in IBD: new insights into pathogenic and therapeutic implications.
Gut.
2005;
54
1481-1491
-
30
Breton A, Mazeli L, Bradesi S, Gercia-Villar R, Fioramonti J, Buéno L, Olives J P.
Fecal calprotectin and transferrin in an animal model of experimental colitis and in children with IBD (abstract).
J Ped Gastroenetrol Nutr.
2001;
32
349
-
31
Olafsdottir E, Aksnes L, Fluge G, Berstad A.
Faecal calprotectin levels in infants with infantile colic, healty infants, children with inflammatory bowel disease, children with recurrent abdominal pain and healthy children.
Acta Paediatr.
2002;
91
45-50
-
32
Fagerberg U L, Lööf L, Myrdal U, Hansson L O, Finkel Y.
Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms.
J Ped Gastroenterol Nutr.
2005;
40
450-455
-
33
Berni Canani R, Rapacciuolo L, Romano M T, Tanturri de Horation L, Terrin G, Manguso F, Cirillo P, Paparo F, Troncone R.
Diagnostic value of faecal calcprotectin in paediatric gastroenterology clinical practice.
Dig Liver Dis.
2004;
36
467-470
-
34
Costa F, Mumolo M G, Ceccarelli L, Bellini M, Romano M R, Sterpi C, Ricchiuti A, Marchi S, Bottai M.
Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease.
Gut.
2005;
54
368
-
35
Langhorst J, Elsenbruch S, Mueller T, Rueffer A, Spahn G, Michalsen A, Dobos G J.
Comparison of 4 neutrophil-derived proteins in feces as indicators of disease activity in ulcerative colitis.
Inflamm Bowel Dis.
2005;
11
1085-1091
-
36
Kolho K L, Raivio T, Lindahl H, Savilahti E.
Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease.
Scand J Gastroenterol.
2006;
41
720-725
-
37
Konikoff M R, Denson L A.
Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease.
Inflamm Bowel Dis.
2006;
12
524-534
-
38
Bousvaros A.
Common errors in the management of children with IBD.
JPGN.
2006;
43(S2)
15
Lt. OA Dr. med. Rüdiger Kardorff
Klinik für Kinder- und Jugendmedizin
Marien-Hospital gGmbH
Pastor-Janßen-Str. 8 - 38
46483 Wesel
Phone: 0281/104-0
Fax: 0281/104-1018
Email: ruediger.kardoff@marien-hospital-wesel.de
Prof. Dr. med. Michael Radke
Klinikum „Ernst von Bergmann”
Zentrum für Kinder- und Jugendmedizin
Charlottenstraße 72
14467 Potsdam
Phone: 0331/24159-01 oder -02
Fax: 0331/2415900
Email: mradke@klinikumevb.de
